Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma (vol 15, pg 737, 2015)

被引：3
|
作者：
Richardson, P. G. [1 ]
Laubach, J. P. [1 ]
Lonial, S. [1 ]
机构：
[1] Univ Navarra Clin, IDISNA, CIMA, Pamplona, Spain
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 09期
关键词：
D O I：
10.1586/14737140.2015.1071726
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1121 / 1121
页数：1
相关论文
共 50 条
  • [41] Novel Agents for Relapsed and/or Refractory Multiple Myeloma
    Thomas, Sheeba K.
    Richards, Tiffany A.
    Weber, Donna M.
    CANCER JOURNAL, 2009, 15 (06): : 485 - 493
  • [42] The novel pan-deacetylase inhibitor panobinostat induces alternative pathways of apoptosis in hepatocellular carcinoma models
    Di Fazio, Pietro
    Schneider-Stock, Regine
    Wissniowski, Till
    Gahr, Susanne
    Neureiter, Daniel
    Ocker, Matthias
    CANCER RESEARCH, 2009, 69
  • [43] Lenalidomide for the treatment of relapsed or refractory multiple myeloma
    Weber, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 22 - 24
  • [44] Treatment Options for Relapsed and Refractory Multiple Myeloma
    Lonial, Sagar
    Mitsiades, Constantine S.
    Richardson, Paul G.
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1264 - 1277
  • [45] Selinexor for the treatment of patients with relapsed or refractory multiple myeloma( vol 30 , pg 535 , 2024)
    Babar, A.
    Babar, M.
    Zubair, H.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (01) : 172 - 172
  • [46] Elotuzumab in the treatment of relapsed and refractory multiple myeloma
    Grosicki, Sebastian
    Bednarczyk, Martyna
    Barchnicka, Agnieszka
    Grosicka, Olga
    FUTURE ONCOLOGY, 2021, 17 (13) : 1581 - 1591
  • [47] Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
    Bumma, Naresh
    Richter, Joshua
    Jagannath, Sundar
    Lee, Hans C.
    Hoffman, James E.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Shah, Mansi R.
    Lentzsch, Suzanne
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Pianko, Matthew J.
    Ye, Jing Christine
    Wu, Ka Lung
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    Martinez-Lopez, Joaquin
    Cassady, Kaniel
    Deveaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Hazra, Anasuya
    Yancopoulos, George D.
    Sirulnik, L. Andres
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Houvras, Yariv
    Dhodapkar, Madhav V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22)
  • [48] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
    Guidetti, Anna
    Prada, Claudia Paba
    Laubach, Jacob P.
    Varga, Cindy
    Maglio, Michelle E.
    McKenney, Mary
    Doss, Deborah
    Schlossman, Robert L.
    Mitsiades, Constantine
    Hideshima, Teru
    Gorgun, Gullu T.
    Ghobrial, Irene M.
    Raje, Noopur
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108
  • [49] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
  • [50] Treatment options for relapsed and refractory multiple myeloma
    Nooka, Ajay K.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Lonial, Sagar
    BLOOD, 2015, 125 (20) : 3085 - 3099
12345